Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Adicet Bio, Inc. (ACET) · filed Jun 29, 2023

Accession no.
0000947871-23-000713
Filed
Jun 29, 2023, 4:46 PM ET
Trade date
Jun 27, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market purchases total $1.83M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Israel GP Ltd.CIK 0001569590Director, 10% Owner
OrbiMed Israel BioFund GP Limited PartnershipCIK 0001569821Director, 10% Owner
OrbiMed Capital GP V LLCCIK 0001615374Director, 10% Owner
OrbiMed Israel GP II, L.P.CIK 0001682090Director, 10% Owner
OrbiMed Advisors Israel II LtdCIK 0001682093Director, 10% Owner
OrbiMed Capital GP VI LLCCIK 0001682115Director, 10% Owner
Chimovits ErezCIK 0001706399Director, 10% Owner
OrbiMed Genesis GP LLCCIK 0001808744Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 27, 2023Common StockPPurchaseAcquired+125,000$2.09F1+$261,2501,027,885IndirectDuplicate filing
Jun 27, 2023Common StockPPurchaseAcquired+250,000$2.09F1+$522,500646,657IndirectDuplicate filing
Jun 27, 2023Common StockPPurchaseAcquired+442,000$2.09F1+$923,7805,685,259IndirectDuplicate filing
Jun 27, 2023Common StockPPurchaseAcquired+58,000$2.09F1+$121,220748,054IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Referenced by the price of 4 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)